1.
Ibanez B, James S, Agewall S, et al.: 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018; 39: 119–77.
2.
Deutsch-österreichische S3-Leitlinie „Infarktbedingter kardiogener Schock – Diagnose, Monitoring und Therapie.“ AWMF-Registernummer 019–013; Entwicklungsstufe 3 (2019).
3.
Zeymer U, Werdan K, Schuler G, et al.: Impact of immediate multivessel percutaneous coronary intervention versus culprit lesion intervention on 1-year outcome in patients with acute myocardial infarction complicated by cardiogenic shock: Results of the randomised IABP-SHOCK II trial. Europ Heart J ACC 2017; 6: 601–9.
4.
de Waha S, Jobs A, Eitel I, et al.: Multivessel versus culprit lesion only percutaneous coronary intervention in cardiogenic shock complicating acute myocardial infarction: A systematic review and meta-analysis. Eur Heart J ACC 2018; 7: 28–37.
5.
Thiele H, Akin I, Sandri M, et al.: CULPRITSHOCK Investigators. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med 2017; 377: 2419–32.
6.
Thiele H, Akin I, Sandri M, et al.: One year outcomes after PCI strategies in cardiogenic shock. New Engl J Med 2018; 379: 1699–710.
7.
Neumann FJ, Sousa-Uva M, Ahlsson A, et al.: 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019; 40: 87–165.
8.
Mehta SR, Wood DA, Storey RF.: et al, COMPLETE trial steering committee and investigators.
Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2019; 381: 1411–21.
9.
Ewig S, Höffken G, Kern WV, et al.: Management of adult community-acquired pneumonia and prevention – Update 2016. Pneumologie 2016; 70: 151–200.
10.
Ben-Ami R, Rodríguez-Baño J, Arslan H, et al.: A multinational survey of risk factors for infection with extended-spectrum betalactamase-producing enterobacteriaceae in non-hospitalized patients. Clin Infect Dis 2009; 49: 682–90.
11.
Creutz P, Kothe H, Braun M, et al.: Failure of ambulatory treatment in CAP patients leading to subsequent hospitalization and its association to risk factors – prospective cohort study. J Pulmon Resp Med 2013; 3:1–7.
12.
DGP Leitlinie zur Diagnostik, Prävention und Therapie der chronisch obstruktiven Lungenerkrankung (COPD), 24. Januar 2018, https://www.awmf.org/leitlinien/detail/ ll/020–006.html.
13.
Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2019 REPORT. goldcopd.org.
14.
Leuppi JD, Schuetz P, Bingisser R, et al.: Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease. JAMA 2013; 309: 2223–31.
15.
Lautz HU, Selberg O, Korber J, et al.: Protein-calorie malnutrition in liver cirrhosis. Clin Investig 1992; 70: 478–86.
16.
Amodio P, Bemeur C, Butterworth R, et al.: The nutritional management of hepatic encephalopathy
in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology 2013; 58: 325–36.
17.
European Association for the Study of the Liver. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol 2017; 66: 1047–81.
18.
Plauth M, Cabre E, Riggio O et al.: ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr 2006; 25: 285–94.
19.
Gerbes AL, Labenz J, Appenrodt B, et al.: Aktualisierte S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) „Komplikationen der Leberzirrhose“ (AWMF 021–017). Z Gastroenterol 2019; 57: 611–80.
20.
Nguyen DL, Morgan T. Protein restriction in hepatic encephalopathy is appropriate for selected patients: a point of view. Hepatol Int 2014; 8: 447–51.
21.
Cordoba J, Lopez-Hellin J, Planas M, et al.: Normal protein diet for episodic hepatic encephalopathy:
results of a randomized study. J Hepatol 2004; 41: 38–43.
22.
Campollo O, Sprengers D, Dam G et al.: Protein tolerance to standard and high protein meals in patients with liver cirrhosis. World J Hepatol 2017; 9: 667–76.
23.
Wijarnpreecha K1, Werlang M2, Panjawatanan P, et al.: Association between sarcopenia and hepatic encephalopathy: A systematic review and meta-analysis. Ann Hepatol 2019. pii: S1665–2681 (19) 32193–3.
24.
Mannucci PM: Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No. J Thromb Haemost 2006; 4: 721–3.
25.
Zakeri N, Tsochatzis EA: Bleeding risk with invasive procedures in patients with cirrhosis and coagulopathy. Curr Gastroenterol Rep 2017; 19: 45.
26.
Grabau CM, Crago SF, Hoff LK, et al.: Performance standards for therapeutic abdominal paracentesis. Hepatology 2004; 40: 484–8.
27.
McVay PA, Toy PT: Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991; 31: 164–71.
28.
Runyon BA: Paracentesis of ascitic fluid. A safe procedure. Arch Intern Med 1986; 146: 2259–61.
29.
Kurup AN, Lekah A, Reardon ST, et al.: Bleeding rate for ultrasound-guided paracentesis in thrombocytopenic patients. J Ultrasound Med 2015; 34: 1833–8.
30.
O’Leary JG, Greenberg CS, Patton HM, Caldwell SH: AGA clinical practice update: coagulation in cirrhosis. Gastroenterology. 2019; 157: 34–43.
31.
Runyon BA, AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013; 57: 651–3.
32.
Intagliata NM, Argo CK, Stine JG, et al.: Concepts and controversies in haemostasis and thrombosis associated with liver disease: Proceedings of the 7th International Coagulation in Liver Disease Conference. Thromb Haemost 2018; 118: 1491–506.
33.
Bundesärztekammer. Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten: mit 19 Tabellen. Dt. Ärzte-Verlag 2009.
34.
Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised trials. Lancet 2019; 393: 07–415.
35.
Han BH, Sutin D, Williamson JD et al.: Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults. The ALLHAT-LLT randomized clinical trial. JAMA Intern Med 2017; 177: 955–65.
36.
Pilotto A, Gallina P, Panza F et al.: Rela tion of statin use and mortality in communitydwelling frail older patients with coronary artery disease. Am J Cardiol 2016; 118: 1624–30.
37.
Kutner JS, Blatchford PJ, Taylor DH et al.: Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting disease: a randomized trial. JAMA Intern Med 2015; 175: 691–700.
38.
Homes HM, Todd A: Evidence-based deprescribing of statins in patients with advanced illness. JAMA Intern Med 2015; 175: 701–2.